Viral myocarditis is an important cause of congestive heart failure (1). In its acute phase, it is associated with systolic dysfunction, myocardial necrosis, and inflammatory cellular infiltration. A clearer understanding of the disease's pathophysiology would help in the choice of appropriate treatment. We have described a murine model of viral myocarditis caused by the encephalomyocarditis virus (EMCV) infection (1, 2) . Pathologic studies performed during the acute phase in this model have shown the onset of visible myocardial changes three days after virus inoculation. Focal myocytolysis appeared on day 3, and necrotic myocardial foci with infiltration of small mononuclear cells and interstitial edema were present on day 5. Expansion of myocardial necrosis was visible after day 7, becoming extensive between day 10 and day 14. Dilation of the left ventricle (LV) was prominent by day 8, increasing further between 10 and day 14, a stage when pleural effusion, pulmonary congestion, and ascites developed (1) . Pathological studies were consistent with death from congestive heart failure, although the hemodynamic characteristics of this and other murine models of viral myocarditis have not been analyzed in detail. This study applied the new conductancemicromanometer system described by Georgakopoulos et al. (3) (4) (5) (6) to measure the LV pressure-volume relationships in the acute phase of myocarditis in our in vivo model. intubation, the cannula was connected to a volume cycled rodent ventilator (Shinano Co., Tokyo, Japan) with supplemental oxygen, a tidal volume of 7 l/g, and a respiratory rate of 140/min. The right carotid artery and external jugular vein were exposed via the same midline incision. To allow the use of a physiologic closed-chest preparation (8), a 1.4F SPR-719 Millar catheter was advanced via the right carotid artery into the ascending aorta for measurements of aortic pressure, then inserted into the LV. Left ventricular pressurevolume relations were measured by transiently compressing the inferior vena cava. The data were recorded as a series of pressure-volume loops (about 20 loops). Parallel volume (V p ) of each mouse was calibrated by the injection of 10 l of hypertonic saline into the external jugular vein (9) . Measurements of right atrial (RA) pressure. A modified 0.014-in. Pressure Wire Sensor (Radi Medical System AB, Uppsala, Sweden) was used for right atrial (RA) pressure measurements (10) . The pressure wire was inserted through the external jugular vein into the RA and connected to the Pressure Wire Interface (Radi Medical System AB, Uppsala, Sweden). The pressure tracings and surface electrocardiogram were monitored online (Biomedical Research System [LEG-1000], Nihon Koden Co., Tokyo, Japan). The RA pressure was measured, and the pressure waveforms and electrocardiogram were digitized at 2 kHz, stored to disk, and analyzed with commercially available software (Nihon Koden Co., Tokyo, Japan). Volume calibration of the conductance catheter. The volume calibration of this conductance system was performed as described by Yang et al. (9) . Briefly, seven cylindrical holes in a block 1-cm deep and with known diameters ranging from 1.4 to 5 mm were filled with fresh heparinized whole murine blood. An interelectrode distance of 4.5 mm was used to calculate the absolute volume in each cylinder. In this calibration the linear volume-conductance regression of the absolute volume in each cylinder versus the raw signals acquired by the conductance catheter was used as the volume calibration formula ( Fig. 1) 
(5).
Analysis of the signals. All pressure-volume loop data were analyzed with the Integral 3 software (Unique Medical Co., Tokyo, Japan). Indexes of contractility and LV stiffness were calculated, including end-systolic pressure (ESP) volume relationship (ESPVR), end-systolic volume (ESV) elastance (E es ), stroke work (SW)-end-diastolic volume relation (preload recruitable stroke work [PRSW]), slope of maximum derivative of change in systolic pressure over time (dP/dt max )-EDV relation [(dP/dt max )/EDV], end-diastolic pressure volume relationship (EDPVR), and end-diastolic volume elastance (E ed ). The E es and E ed were normalized by 100 mg of heart weight. The ventricular-to-vascular coupling ratio was assessed by the arterial elastance (E a )-to-E es ratio (E a /E es ). The time constant of isovolumic relaxation () was also calculated by linear regression of dP/dt max versus pressure from data between the minimum derivative of change in diastolic pressure over time (dP/dt min ) and 5 mm Hg above EDP. Stroke volume (SV), cardiac output (CO), and SW were normalized by body weight (stroke volume index [SVI], cardiac index [CI] , and SW index [SWI], respectively). The systemic vascular resistance index (SVRI) was calculated by the following equation: SVRI ϭ [mean aortic pressure (AO mean ) Ϫ mean RA pressure (RA mean )]/CI. Experimental infection. A dose of 0.1 ml of the M variant of EMCV diluted in Eagle's modified essential medium (Nissui Pharmaceutical Co., Tokyo, Japan) to a concentration of 1,000 plaque-forming U/ml was inoculated intraperitoneally in 32-day-old, 17 g, inbred male DBA/2 mice (7). A dose of 0.1 ml of phosphate-buffered saline was inoculated intraperitoneally to uninfected control mice. The day of virus inoculation was defined as day 0. namic measurements were made in both groups on days 0, 1, 3, 4, 5, 7, 9, 12, and 14. The animals were randomly selected to be catheterized at each time point. In the infected group, when the measurements could not be made for technical reasons, for instance when the animal died of cardiogenic shock during the operation, or because of arrhythmias, the data were excluded from analysis. None of the uninfected mice died during an experiment. After the successful collection of hemodynamic measurements, the mice were sacrificed, the hearts were removed, and body and heart were weighed. Statistical analysis. Statistical comparisons were made by analysis of variance with unpaired Student t test. The standard volume lines were analyzed by simple linear regression. Values are expressed as mean Ϯ SE. A p value Ͻ 0.05 was considered statistically significant.
RESULTS
Time course of hemodynamic function in uninfected versus infected mice. Table 1 compares multiple indexes of hemodynamic function in control versus infected mice on day 1, day 7, and day 14. No difference was found between the two groups at baseline. Heart rate remained stable in both groups over the 14 days of observation.
Day 1.
On day 1, at a stage when the hearts of infected mice show no gross pathologic changes (1), contractility was enhanced, diastolic function was abnormal, and EDP was increased in the group of infected animals (Figs. 2A and 2B). The ESPVR in the infected mice had a markedly steeper slope in comparison with controls ( Fig. 2A) . The normalized E es (NL E es ) of the infected mice was significantly greater than that of the uninfected mice (p Ͻ 0.05) ( Table 1 , Fig. 3A) . Consistent with the changes in ESPVR, PRSW and (dP/dt max )/EDV in infected mice were significantly greater than in controls ( Table 1) . The dP/dt max and dP/dt min were significantly increased in the infected group (Table 1, Fig. 2B ), although these two parameters vary with chamber volume, contractility, and heart rate. To normalize for these factors, dP/dt max /dP/dt min ( Fig. 3C) , which is independent of preload and afterload (4, 5) , was calculated and was increased by approximately 72% in the infected compared with the uninfected mice. In addition, , an index of diastolic relaxation, was significantly longer in infected than in uninfected mice (p Ͻ 0.01, Table 1 ). Prolongation of and an increase in dP/dt max /dP/dt min are both indicative of a delayed diastolic relaxation in the infected animals.
In addition to a delayed relaxation, chamber compliance was decreased in the infected group. Figure 2A also shows a markedly steeper slope of EDPVR in the infected group in 
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Hemodynamics of Acute Viral Myocarditis comparison with controls. Normalized E ed (NL E ed ) in the infected mice was significantly greater than in the uninfected mice (p Ͻ 0.05; Table 1 , Fig. 3B ). The EDP (Table 1 , Fig. 4A ) was significantly increased in the infected mice compared with controls (p Ͻ 0.05), and EDV (Table 1 , Fig.  4B ) was decreased, though this difference was not statistically significant. End-systolic pressure (Table 1 , Fig. 4A ) (p Ͻ 0.01), CI (Fig. 5A ), ejection fraction (EF) (Fig. 5B) , and SVI (Table 1) were significantly higher in the infected group than in the uninfected group (p Ͻ 0.05). Finally SVRI, an index of afterload, was significantly increased in the infected group (p Ͻ 0.05, Table 1 ). Day 3. On day 3, a stage at which small foci of myocardial necrosis are found without evidence of cellular infiltration (1), abnormal diastolic function persisted in the infected mice, however, without findings of enhanced contractility (Fig. 3A) . The NL E es, PRSW, and (dP/dt max )/EDV were comparable in both groups (Fig. 3A) . , dP/dt max /dP/dt min , dP/dt min , and NL E ed were significantly increased in the infected mice as well as EDP (p Ͻ 0.05, Figs. 3B and 3C, and 4A). End-systolic pressure, ESV, EDV, SVI, EF, CI, dP/dt max , RA mean , and SVRI were comparable in both groups (Figs. 4A and 4B, and 5A and 5B). Day 4. On day 4, contractility began to fall in the infected mice (Fig. 3A) . The NL E es and (dP/dt max )/EDV of the infected mice were significantly lower than in the uninfected mice (p Ͻ 0.05). Delayed diastolic relaxation persisted, and decreased chamber compliance further decreased. , dP/ dt max /dP/dt min , and dP/dt min were significantly increased in the infected mice (p Ͻ 0.01, Fig. 3C ), along with NL E ed , EDP, and RA mean , compared with controls (p Ͻ 0.01, Figs. 2B and 3A). Ejection fraction was significantly lower (p Ͻ 0.05, Fig. 5B ), though SVI and CI were compensated by body weight loss (Fig. 5A ). End-systolic pressure, EDV, and dP/ dt max were comparable in both groups (Figs. 4A and 4B). Day 5. On day 5, decreased contractility and abnormal diastolic function had progressed, the chambers began to dilate, and cardiac output fell in the infected animals (Figs. 3A to 3C, 4B, and 5A). End-diastolic volume and ESV were significantly greater in the infected than uninfected mice (p Ͻ 0.05 and p Ͻ 0.01, respectively, Fig. 4B ). The NL E es , PRSW, (dP/dt max )/EDV, and dP/dt max had fallen significantly in the infected mice compared with the controls (p Ͻ 0.05, Fig. 3A) . In contrast, , dP/dt max /dP/dt min , dP/dt min , NL E ed , EDP, and RA mean had increased significantly (Figs. 3B and 3C, and 4A). Finally, EF and CI were decreased in the infected group (Figs. 5A and 5B), while SVI and ESP were comparable in both groups (Fig. 4A) . Day 7. Changes consistent with heart failure culminated on day 7. Decreased contractility, abnormal diastolic function, chamber dilation, and low output had each progressed in the infected mice (Figs. 2C and 2D, 4A and 4B, and 5A and 5B). The NL E es , PRSW, (dP/dt max )/EDV, dP/dt max , EF, ESP, CI, and SVI were significantly depressed in the infected compared with the uninfected mice (Table 1) . Accordingly, , dP/dt max /dP/dt min , and dP/dt min were significantly, and EDV, ESV, NL E ed , EDP, and RA mean markedly increased in the infected mice compared with the controls (Table 1 ). Figure 3 . Evolution of contractility, myocardial relaxation, and chamber compliance. Open circles ϭ uninfected control group; solid circles ϭ infected group. dP/dt max ϭ slope of maximum derivative of change in systolic pressure over time; dP/dt min ϭ minimum derivative of change in diastolic pressure over time; NL E ed ϭ normalized end-diastolic volume elastance; NL E es ϭ normalized end-systolic volume elastance. *p Ͻ 0.05; **p Ͻ 0.01 versus control. n ϭ 5 in each measurement.
Days 9 to 14. Abnormal systolic and diastolic dysfunction receded, though chamber dilation progressed between day 9 and day 14 (Figs. 2E and 2F, 4A and 4B, and 5A and 5B). Though ESP, EDP, ESV, EF, dP/dt max , dP/dt min , dP/ dt max /dP/dt min , , NL E es , PRSW, (dP/dt max )/EDV, AO mean , and RA mean each returned toward baseline between days 9 and 14, the differences between infected and uninfected groups on day 14 remained statistically significant (Figs. 2E and 2F, 4A and 4B, and 5B, Table 1 ). In contrast, SVI, CI, and NL E ed returned toward baseline between days 9 and 14 to an extent such that the differences between infected animals and controls were no longer significant on day 14 (Fig. 5A , Table 1 ). End-diastolic volume continued to increase past day 9 and, on day 14, remained significantly greater in the infected than in the uninfected mice (Fig. 4B) . The SVRI remained comparable in both groups from day 3 to day 14, while E a rose significantly between day 4 and day 12 in the infected group (Table 1) . Time course of efficiency of LV work. Efficiency of LV work (SW/PVA) was depressed in the infected mice on day 4, when the contractility began to decrease (Fig. 5C ). The fall in efficiency reached a nadir of 13.4 Ϯ 2.9% on day 7, in contrast with 78.6 Ϯ 1.4% in the uninfected group. Past day 9, the efficiency in the infected mice recovered, though remained significantly decreased on day 14 (p Ͻ 0.05). Concordant with these measurements of efficiency, E a /E es increased past day 4 in the infected mice, reached its peak on day 7, and recovered between day 9 and day 14 ( Table 1) . The SWI was decreased on day 5 when CI began to decrease in the infected group, reached its peak on day 7, and recovered between day 9 and day 14 ( Table 1) .
DISCUSSION
This study revealed that acute myocarditis induced by EMCV was characterized by three phases of hemodynamic evolution (Fig. 6): 1) A hyperdynamic phase was observed from day 1 to day 3.
In this phase, increases in contractility, cardiac output, ESP, and vascular resistance were observed, probably 
1511
Hemodynamics of Acute Viral Myocarditis from activation of sympathetic activity, as has been described in another type of viral infection (11) . A hyperdynamic state is often clinically observed in the hyperacute phase of myocarditis, though has not been specifically reported. It is noteworthy that diastolic dysfunction was found concomitantly. Abnormal relaxation and increased chamber stiffness were present, despite the known improvement in diastolic function expected from catecholamines (12) . This diastolic dysfunction may be caused by direct viral activity. Murine cardiac troponin T is increased, and plaque assay shows the presence of EMCV in the myocardial homogenate as early as day 1 in this same model (13) (unpublished data). Trivial injury to the plasma membrane and myocardial structural proteins may be caused by the initial viral attack on the myocytes, despite the absence of gross pathologic abnormalities on day 1. Other immune mediators, including cytokines and proteins induced by EMCV, may cause this abnormal diastolic function. 2) A depressive phase was observed between day 4 and day 7, characterized by a progressive fall in contractility, lower cardiac output, impaired myocardial relaxation, and decreased chamber compliance. Left ventricular dilation was observed past day 5, while, on day 7, cardiogenic shock and severe congestion were documented in these experiments. Impaired contractility may be caused directly by myocyte injury and indirectly by nitric oxide (NO) and cytokines, including tumor necrosis factor-␣ and interleukin-1␤. We have reported, in this model, the expression of messenger RNA of inducible NO synthase and of these cytokines, and the importance of these mediators in its pathophysiology (13) (14) (15) (16) (17) . The expression of these cytokines was significantly increased on day 3 and peaked on day 7 (13). Recent reports have emphasized the importance of NO and cytokines in the pathophysiology of congestive heart failure (13-21). The well-described direct and indirect negative inotropic effects of these immune-mediators are suspected to explain the decrease in myocardial contractility observed in this model (22) (23) (24) (25) . In addition, the progressive diastolic dysfunction occurring during this phase may be caused by myocytic injury, interstitial edema, and cellular infiltrations. It has been reported that NO, in contrast with its negative effects on systolic function, probably improves diastolic function, and is one of the mediators involved in compensatory mechanisms (26) . However, the tissue injury due to viral infection apparently prevailed over the beneficial effects on diastolic function conferred by NO. 3) A recovery phase was observed between day 9 and day 14, during which contractility recovered slightly, and chamber compliance improved markedly. The decrease in contractility may have been caused by a fall in the production of NO and cytokines, while the improvement in chamber compliance may be explained by regressions in interstitial edema and inflammatory cellular infiltrations (1,2,13). Vascular resistance was not different between the two groups, perhaps because of production of NO and cytokines.
To the best of our knowledge, this is the first report of hemodynamic measurements, particularly of pressurevolume relationship and RA pressure, in an animal model of Figure 5 . Evolution of cardiac output, ejection fraction (EF), and left ventricular work efficiency. Open circles ϭ uninfected control group; solid circles ϭ infected group. *p Ͻ 0.05; **p Ͻ 0.01 versus control. n ϭ 5 in each measurement. CI ϭ cardiac index. viral myocarditis. Our immunologic and molecular biologic studies of viral myocarditis in an EMCV animal model, which began in 1982, have provided important insights into the mechanisms of the disease. In this new hemodynamic study, distinct pathophysiologic abnormalities were identified, including a rapid and persistent fall, after an early increase, in systolic function, although, on day 14 the animals remained apparently vigorous. In contrast, diastolic function decreased from day 1 to day 7, then improved markedly to day 14. This improvement in diastolic function compensated for systolic dysfunction, with remodeling and dilation of the LV chamber. Therefore, the vitality of the mice may have reflected the recovery from congestion by an improvement of chamber compliance. These functional anomalies and remodeling process are the results of direct viral attack, immunological responses, including cytokine production, and of endocrine activity probably vastly different from the pathophysiology involved in ischemic or valvular heart disease. A detailed description of the time course of hemodynamic alterations and remodeling occurring in the acute phase of viral myocarditis, as is presented for the first time in this report, should be clinically helpful to diagnose the disease, as well as plan its management. Study limitations. We recognize some limitations in our investigations. First, V p was calibrated by the hypertonic saline method. This method assumes that hemodynamics are unchanged by the bolus of hypertonic saline (27) . However, volume loading and the hypertonicity of the solution may both modify hemodynamics in this model. There were no significant differences in EDP, ESP, dP/ dt max , and dP/dt min between measurements made immediately before the saline bolus and those made for the determination of V p in either the uninfected or the infected group over the two weeks of study (Table 2) . However, a volumetric analysis was not performed. Ultrasonic crystal measurements in mice have been reported, a method used in open-chest conditions (28) . While this method accurately estimates LV volume, it could not be applied in this study, because after day 5, the infected mice were intolerant of open-chest surgery and any invasive cardiac intervention, Values are means Ϯ SE. There was no significance between data from immediately before saline bolus (baseline) and the peak of data acquisition for the determination of V p (saline) of both uninfected and infected groups. n ϭ 5 in each. For abbreviations, see the Abbreviation Box.
